Although the lack of precise specificity can contribute to side effects in patients and can be seen as a disadvantage, experience from our laboratory has shown that it is often advantageous to inhibit more than one receptor tyrosine kinase in any tumor treatment. Here, NTRK1 is linked to neoplasm.